CytoPherx Obtains $34,000,000 New Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=19b2d357-f166-424f-a518-d25bffad22b0&Preview=1 -
Date
1/4/2012 -
Company Name
CytoPherx -
Mailing Address
401 W. Morgan Rd. Ann Arbor, MI 48108 -
Company Description
CytoPherx, Inc., founded in July 2007 and headquartered in Ann Arbor, Michigan, is a venture-backed, clinical stage medical device company addressing inflammation-based diseases and conditions with a proprietary selective cytopheresis system. -
Website
http://www.cytopherx.com -
Transaction Type
Venture Equity -
Transaction Amount
$34,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
The funds will be used to complete U. S. clinical trials and gain FDA approval to commercialize the CytoPherx anti-inflammatory therapy for acute kidney injury. -
M&A Terms
-
Venture Investor
Early Stage Partners -
Venture Investor
ONSET Ventures -
Venture Investor
Capital Midwest Fund -
Venture Investor
Kaiser Permanente Ventures -
Venture Investor
Emergent Medical Partners -
Venture Investor
Aphelion Capital -
Venture Investor
Lurie Investments -
Venture Investor
Apjohn Ventures Fund
